GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Michael A. Nauck; Daniel R. Quast; Jakob Wefers; Juris J. Meier

doi:10.1016/j.molmet.2020.101102

Keywords

ExenatideDulaglutideLixisenatideLiraglutideMedicineSemaglutideGastric emptyingType 2 diabetesGlucagon-like peptide 1 receptorInternal medicineEndocrinologyWeight lossPharmacologyAgonistDiabetes mellitusReceptorStomachObesity

Affiliated Institutions

Related Publications

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Daniel J. Drucker

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secr...

2018 Cell Metabolism 1589 citations

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

Louise Robinson , Tim Holt , Karen Rees +2 more

Objectives To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight. Design Meta-analysis of available data from...

2013 BMJ Open 288 citations

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Lotte Bjerre Knudsen , Lars Wichmann Madsen , Søren Andersen +15 more

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog developed for type 2 diabetes. Long-term liraglutide exposure in rodents was associated with thyroid C-cell hyperplasia a...

2010 Endocrinology 609 citations

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

Michael A. Nauck

Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin ...

2015 Diabetes Obesity and Metabolism 411 citations

Cardiovascular Actions of Incretin-Based Therapies

John R. Ussher , Daniel J. Drucker

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment ...

2014 Circulation Research 335 citations

Publication Info

Year: 2020
Type: review
Volume: 46
Pages: 101102-101102
Citations: 1286
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1286

OpenAlex

Cite This

APA Style

                            
                                    Michael A. Nauck, 
                                
                                    Daniel R. Quast, 
                                
                                    Jakob Wefers
                                
                                et al.
                            
                            (2020). 
                            GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. 
                            Molecular Metabolism
                            , 46
                            
                            , 101102-101102.
                            https://doi.org/10.1016/j.molmet.2020.101102

Identifiers

DOI: 10.1016/j.molmet.2020.101102